Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V590 in Healthy Adults
NCT04569786Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V590 in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With at Least 1 Solicited Injection Site Adverse Event, Percentage of Participants With at Least 1 Solicited Systemic Adverse Event and 3 more. Started Oct 2020; status: terminated.
02
Drugs
V590
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04569786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569786.